TW383303B - 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one having dopamine receptor cooperativity - Google Patents

4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one having dopamine receptor cooperativity Download PDF

Info

Publication number
TW383303B
TW383303B TW087101495A TW87101495A TW383303B TW 383303 B TW383303 B TW 383303B TW 087101495 A TW087101495 A TW 087101495A TW 87101495 A TW87101495 A TW 87101495A TW 383303 B TW383303 B TW 383303B
Authority
TW
Taiwan
Prior art keywords
compound
hydrogen
patent application
scope
dihydro
Prior art date
Application number
TW087101495A
Other languages
English (en)
Chinese (zh)
Inventor
Richard Eric Mewshaw
James Albert Nelson
Uresh Shantilal Shah
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of TW383303B publication Critical patent/TW383303B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW087101495A 1997-02-18 1998-02-05 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one having dopamine receptor cooperativity TW383303B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80187097A 1997-02-18 1997-02-18

Publications (1)

Publication Number Publication Date
TW383303B true TW383303B (en) 2000-03-01

Family

ID=25182225

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087101495A TW383303B (en) 1997-02-18 1998-02-05 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one having dopamine receptor cooperativity

Country Status (14)

Country Link
EP (1) EP0964853A1 (pt)
JP (1) JP2001511804A (pt)
KR (1) KR20000071160A (pt)
CN (1) CN1138761C (pt)
AR (1) AR011138A1 (pt)
AU (1) AU744443B2 (pt)
BR (1) BR9807703A (pt)
CA (1) CA2278747A1 (pt)
HU (1) HUP0001262A3 (pt)
IL (1) IL131156A0 (pt)
NZ (1) NZ337271A (pt)
TW (1) TW383303B (pt)
WO (1) WO1998035946A1 (pt)
ZA (1) ZA981310B (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9210632D0 (en) * 1992-05-19 1992-07-01 Fisons Plc Compounds
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
AR004523A1 (es) * 1995-11-06 1998-12-16 American Home Prod 2-(AMINOMETIL)-3,4,7,9-TETRAHIDRO-2H-PIRANO-[2,3e] INDOL-8-ONAS Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
AU4091797A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy-indolone derivatives as dopamine d2 agonists
EP0923551B1 (en) * 1996-08-27 2002-06-05 American Home Products Corporation 4-aminoethoxy indolone derivatives

Also Published As

Publication number Publication date
ZA981310B (en) 1999-08-17
JP2001511804A (ja) 2001-08-14
NZ337271A (en) 2001-01-26
CN1252060A (zh) 2000-05-03
AR011138A1 (es) 2000-08-02
HUP0001262A3 (en) 2002-04-29
CA2278747A1 (en) 1998-08-20
EP0964853A1 (en) 1999-12-22
BR9807703A (pt) 2000-05-02
WO1998035946A1 (en) 1998-08-20
AU6023498A (en) 1998-09-08
AU744443B2 (en) 2002-02-21
HUP0001262A2 (hu) 2001-04-28
IL131156A0 (en) 2001-01-28
KR20000071160A (ko) 2000-11-25
CN1138761C (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
TW504510B (en) 2,4-diaminopyrimidine derivatives
WO2018231745A1 (en) Compounds for modulating s1p1 activity and methods of using the same
KR100453078B1 (ko) 신규 티오우레아 화합물 및 이를 함유하는 약제학적 조성물
TW306921B (pt)
RU2535200C2 (ru) Соединения n-фенил(пиперазинил или гомопиперазинил)бензолсульфонамида или бензолсульфонилфенил(пиперазина или гомопиперазина), пригодные для лечения заболеваний, которые реагируют на модулирование рецептора 5-нт6 серотонина
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
IE43768B1 (en) Oximes
CN101115717A (zh) 作为选择性5ht2a拮抗剂的取代的二芳基和杂芳基化合物
DE69617995T2 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
CN101119965A (zh) 萘满和茚满衍生物及其用途
CN101679397A (zh) 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物
CN1938023A (zh) 离子通道调节剂
BRPI0712483A2 (pt) sais de ácido clorìdrico de 6-metóxi-8-[4-1-(5-flúor)-quinolin-8-il-piperidin-4-il)-pip erazin-1-il]-quinolina
CN101421234A (zh) 适于治疗对5-羟色胺5ht6受体调节有反应的病症的杂环芳基砜
CN101263136A (zh) 作为5-ht6、5-ht24的苯并咪唑衍生物
BRPI0713107A2 (pt) sais de siccinato de 6-metoxi-8-[4-(1-(5-flúor)-quinolin-8-ila-piperidin-4-ila)- piperazin-1-ila]-quinolina, e formas cristalinas destes
TW383303B (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one having dopamine receptor cooperativity
CN101827828A (zh) 作为5-羟色胺能调节剂的1,2,4-三唑衍生物
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
PT855397E (pt) (r)-5-bromo-n-(1-etil-4-metil-hexa-hidro-1h-1,4-diazepin-6-il)-2-metoxi-6-metilamino-3-piridinocarboxamida processo para a sua preparacao e composicao farmaceutica contendo o referido composto
CN102382032A (zh) 1-(苯基)-4-[3-(4-吲哚氧基)-2-羟基丙基]哌嗪衍生物及其盐、制备方法和应用
CA2307114A1 (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1d.alpha. antagonists
JP2012525355A (ja) セロトニン5−ht6受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
BRPI0713101A2 (pt) formas cristalinas de 6-metoxi-8-[4-(1(5-fluoro)-quinolin-8-il-piperidin-4-il)-pi perazin-1-il]-quinolina
WO2016149324A1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees